- Home
- BILI vs IBRX Comparison
BILI vs IBRX Comparison
Compare BILI & IBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BILI | IBRX |
|---|---|---|
| Founded | 2009 | 2014 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.3B | 7.5B |
| IPO Year | 2017 | 2015 |
Fundamental Metrics
Financial Performance| Metric | BILI | IBRX |
|---|---|---|
| Price | $17.98 | $7.60 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 7 |
| Target Price | ★ $31.13 | $12.57 |
| AVG Volume (30 Days) | 2.0M | ★ 9.0M |
| Earning Date | 05-19-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 38.71 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $113,288,000.00 |
| Revenue This Year | $11.77 | $88.59 |
| Revenue Next Year | $9.59 | $131.15 |
| P/E Ratio | $122.37 | ★ N/A |
| Revenue Growth | N/A | ★ 668.31 |
| 52 Week Low | $15.79 | $1.95 |
| 52 Week High | $36.40 | $12.43 |
Technical Indicators
Market Signals| Indicator | BILI | IBRX |
|---|---|---|
| Relative Strength Index (RSI) | 48.21 | 51.28 |
| Support Level | $17.13 | $6.68 |
| Resistance Level | $19.10 | $8.46 |
| Average True Range (ATR) | 0.40 | 0.38 |
| MACD | 0.01 | 0.05 |
| Stochastic Oscillator | 43.13 | 89.05 |
Price Performance
Historical ComparisonAbout BILI Bilibili Inc.
Bilibili is a Chinese online entertainment platform best known for its YouTube-like video-sharing service. Founded in 2009, it initially focused on long-form content centered around anime, comics, and gaming, or ACG, catering primarily to Generation Z users. Over time, the platform has expanded its content ecosystem to cover a broader range of interests, successfully attracting a more diverse audience beyond its original Gen Z base.
About IBRX ImmunityBio Inc.
ImmunityBio Inc is a biotechnology company focused on developing and commercializing next-generation immunotherapies designed to activate the patient's immune system and provide durable protection against cancer and infectious diseases. Its approach harnesses both the adaptive and innate immune systems with the Cancer BioShield platform. The platform is built around the proprietary IL-15 superagonist ANKTIVA (nogapendekin alfa inbakicept) and is supported by a portfolio that includes adenovirus-vectored vaccines, NK-cell therapies, and additional immunomodulators. The company operates in the United States and Europe, with the majority of its revenue coming from the United States.